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Abstract 
Many infants have some form of gastroesophageal reflux (GER) characterized by 
occasional spitting up with burps.  Symptomatic reflux called gastroesophageal reflux disease 
(GERD) affects infants and causes a variety of symptoms and observable events.  The diagnosis 
of GER or GERD appears to be increasing in the infant population including healthy newborns
and those infants hospitalized for a variety of reasons.  The purpose of this systematic review is 
to identify evidence-based practice guidelines for the treatment of GERD, including 
pharmacologic and non-pharmacologic interventions in the neonatal/infant population.  The 
results of this study show that conservative therapies should be used initially in the treatment of 
GERD. If conservative therapies are unsuccessful, interventions including feedings can be used 
prior to the addition of pharmaceutical therapies.
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Chapter 1. Introduction 
Introduction to the Problem 
Gastroesophageal reflux (GER) refers to the presence of gastric contents in the 
esophagus proximal to the stomach (Mohan & Soni, 2002).  Symptomatic reflux called 
gastroesophageal reflux disease (GERD) includes infants who have a variety of symptoms and 
observable events including vomiting more than two times per day, desaturations, arching, 
drooling, recurrent pneumonias, stridor, recurrent coughs, irritability with feeding, apnea, and 
bradycardia (Mohan & Soni, 2002).  GERD may be associated with significant sequelae 
including poor weight gain and chronic respiratory problems (Mohan & Soni, 2002).  The 
reported incidence of GER in preterm infants varies and ranges from 22% up to 85% Tipnis & 
Tipnis, 2009). The diagnosis of GER or GERD appears to be increasing in the infant 
population including healthy newborns and those infants hospitalized for a variety of reasons.  
Many of those hospitalized children are discharged home on some type of reflux medication 
(Orenstein & Hassall, 2007). 
While evidence suggests that GER is common in most infants and that the incidence of 
GER decreases with increasing gestational age, there is a variety of treatment measures used 
in the neonatal intensive care unit (NICU) often without the diagnosis of GERD.  These 
treatments are not without risks and side effects.  While some treatments are as benign as 
elevating the head of an infant’s bed to prevent reflux, others include medications that have 
been shown to increase the risk of other illnesses including acute gastroenteritis and 
pneumonia (Canani, et al, 2006).  
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Background to the Study 
Diagnosis of gastroesophageal reflux (GER) or gastroesophageal reflux disease 
(GERD) is sometimes difficult due to the controversy in diagnostic indicators.  For example, 
the esophageal pH probe detects reflux of gastric contents by placing a pH probe into the 
lower third of the esophagus via nasal passage. The test measures the level of acidity of the 
reflux contents in the esophagus. This test can last up to 24 hours, and incorrect probe 
placement can produce inaccurate results.  In addition, milk can act as a buffer to acidity after 
feedings which makes acid detection difficult (Martin & Hibbs, 2009).  Intraluminal 
impedance, also known as multiple intraluminal impedance (MII), uses a catheter similar to a 
pH probe and measures the impedance from multiple intraluminal sensors.  The detection of
GER is based on changes in electrical resistance to current flow between electrodes.  This is 
an emerging technology that may be better able to detect reflux (Martin & Hibbs, 2009).   
Upper gastrointestinal studies with small bowel follow through can be used to detect 
GER, but these also have limitations.  They require the use of barium which some infants 
have trouble tolerating. In addition, these studies capture a moment in time rather than a 
period over time.  Unless the infant has an episode of reflux during this test, it will not be 
detected (Martin & Hibbs, 2009). 
In the Neonatal Intensive Care Unit (NICU), gastroesophageal reflux is commonly 
reported by the nursing staff based on observable behaviors by infants including arching, 
irritability, desaturations, apnea, and bradycardia.  Many infants are placed on a variety of 
pharmacologic agents to treat reflux, often without actual confirmed diagnosis of GERD.  
Pharmacologic therapies consist of acid suppression agents, such as H2 receptor antagonists, 
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proton pump inhibitors, and prokinetic agents which improve gastric emptying.  A common 
drug used to treat GERD is ranitidine, an H2 receptor antagonist, but its efficacy in the 
treatment of GERD in infants has not been demonstrated (Martin & Hibbs, 2009).  
Omeprazole and lansoprazole, both proton pump inhibitors, are used frequently in the 
treatment of GERD because of their acid reducing capabilities.  There are concerns with using 
acid suppression agents because of the risks of both necrotizing enterocolitis and altered 
gastric colonizations (Martin & Hibbs, 2009).   
Metoclopramide, a prokinetic agent, increases gastric emptying to decrease the amount 
of contents in the stomach.  This drug is indeed used frequently in the pediatric population.  
However, the North American Society of Pediatric Gastroenterology, Hepatology, and 
Nutrition does not support its use in the pediatric population because there is limited clinical 
evidence of its efficacy (Vandenplas, et al, 2009).
Statement of the Problem 
Gastroesophageal reflux disease (GERD) treatment is not standardized.  There are no 
clear guidelines to determine the use of pharmacologic or non-pharmacologic therapies 
depending on severity of disease. In addition, partially due to the controversies with 
diagnostic indicators, follow-up to determine effectiveness of the treatment used is 
inconsistent.
Purpose of the Study 
 The purpose of this systematic review is to identify evidence-based practice 
guidelines for the treatment of GERD, including pharmacologic and non-pharmacologic 
interventions in the neonatal/infant population.  In addition, treatment efficacy of 
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pharmacologic and non-pharmacologic modalities will be addressed.   
Formal Research Question 
This research addresses the question: what are the best practices in the treatment of 
gastroesophageal reflux disease in the neonatal/infant population?
Answering the above question may help practitioners to better understand the 
treatment regimens associated with GERD.  Evidence-based practice guidelines have the 
potential to decrease the usage of pharmacologic agents that may affect long term outcomes 
for infants, decrease side effects from their usage, and decrease costs to patients and families.   
Significance of the Study 
The diagnosis and treatment of GERD varies greatly among practitioners and often the 
treatment comes without an actual diagnosis.  In a recent study, Khoshoo, et al. (2009),
showed that 42 of 44 infants were on antireflux medications with only 8 of these infants 
showing abnormal acid reflux on a pH probe study.  The costs associated with the treatment 
of GERD, including the diagnosis and pharmacologic agents, continue to increase.  A 
systematic review of available literature regarding neonates and infants with gastroesophageal 
reflux will help to identify best practices for the treatment of GERD in this population.  This 
is important to healthcare administrators as some treatments may not be necessary or are used 
with an increased risk of additional illnesses.  In addition, since the research shows that 
GERD may resolve over time (Suwandhi, et al, 2006), there is potential to use fewer 
pharmacologic agents.  This has the potential to significantly decrease costs to families and 
decrease lost charges/reimbursements to hospitals.  Attempts to standardize the treatment of
GERD can improve the quality of care in the NICU and increase patient safety. 
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Definition of Terms 
Gastroesophageal reflux (GER) refers to the presence of gastric contents in the esophagus 

proximal to the stomach (Mohan & Soni, 2002). 

Gastroesophageal reflux disease (GERD) is symptomatic GER and includes a variety of 

symptoms and observable events (Mohan & Soni, 2002). 

Neonates are babies from birth to 4 weeks old. 

Infants are babies from one month to 1 year old. 

Organization of the Remainder of the Paper 
The following chapters will address the purpose, search strategy, levels of research, and 
grading of studies. Papers that met the inclusion criteria are summarized and are reported in the 
results section. The review provides suggestions for evidence-based guidelines for the treatment 
of GERD. 
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Chapter 2. Methodology 
Purpose/Question
Gastroesophageal reflux disease (GERD) is treated frequently in the neonatal/infant 
population. This is often done without confirmatory diagnosis and without evaluation of efficacy.   
Some medications commonly prescribed for treatment are associated with side effects.  In addition, 
these medications can be expensive, creating a burden for families.  The question addressed by this 
project is: what are the best practices in the treatment of gastroesophageal reflux disease in the 
neonatal/infant population?
Research Methodology 
A systematic review of the literature was conducted for this study.  Because there are not 
currently evidence-based practice guidelines for the treatment of gastroesophageal reflux disease, 
an analysis of the data is warranted. Systematic reviews are the cornerstone of evidence-based 
practice and, if performed in a structured way, are replicable. The Cochrane Consumer Network 
defines a systematic review as a study that summarizes available healthcare studies to provide a 
higher level evidence to increase the effectiveness of healthcare interventions (Cochrane Consumer 
Network, n.d.).
Search Strategy 
The following databases were searched for relevant articles:  PubMed, CINAHL, 
MEDLINE, EMBASE, and the Cochrane Library.  The following search terms were used in the 
search: gastroesophageal reflux, gastro-esophageal reflux, gastro-oesophageal reflux, drug 
therapy, diet therapy, and therapy. Only full text articles available through the Regis Library and 
The Children’s Hospital Library were reviewed. 
  
 
 
 
 
 
 
 
 
  
    
 
  
  
   
7 
Inclusion Criteria 
1.	 Studies that address neonates and infants (babies from birth to 23 months) and 
preterm infants (those born before 37 weeks post conceptual age); 
2.	 Studies that address treatments for gastroesophageal reflux; 
3.	 Studies that include children up to 5 years old; 
Exclusion Criteria 
1.	 Studies published prior to 2004; 
2.	 Studies not published in English; 
3.	 Studies that did not address gastroesophageal reflux as the main subject of the article; 
4.	 Studies that address gastroesophageal reflux as a co-morbidity; 
5.	 Studies that focus treatments on adults; 
6.	 Studies that focus on surgical interventions as a form of treatment; 
7.	 Studies that address subjects that have already had a surgical intervention for 

gastroesophageal reflux. 

Grading of Studies 
Studies were assessed using the Level of Evidence Rating System for evaluation from 
Stetler, et al, (1998). The levels are summarized below: 
Levels of Evidence: 
 Level I: Meta-analysis or systematic review of multiple controlled studies or
 clinical trials
 Level II: Individual experimental studies with randomization  
 Level III: Quasi-experimental studies such as nonrandomized controlled single-
Group, pre-post, cohort, time series, or matched case-controlled studies
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 Level IV: Nonexperimental studies, such as comparative and correlational 
  descriptive research as well as qualitative studies
 Level V: Program evaluation, research utilization, quality improvement projects, 
  case reports 
 Level VI: Opinions of respected authorities; or the opinions of expert committee, 
  including their interpretation of non-research based information.  
Once each study is classified by level, grades will be assigned based on the following criteria: 
 Grade A: Consistent level I studies 
 Grade B: Consistent level II or III studies or extrapolations from level 1 studies  
 Grade C: Level IV studies or extrapolations from level 2 or 3 studies 
 Grade D: Level V or VI evidence or troublingly inconsistent or inconclusive studies of 
any level
Grade C and D studies will not be used in recommendations. 
Sample Size 
Sample size was determined by the available data in the established published time 
frame.  Saturation of the data was reached within the review articles.  Eighty-six of the original 
442 articles met the inclusion criteria and were used in the study. 
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Chapter 3: Results
The initial search in PubMed which includes MEDLINE, EMBASE, and the Cochrane 
Database yielded 424 results. Of those 424 articles, 78 were duplicated. Two hundred and sixty 
one articles were removed due to the defined inclusion/exclusion criteria.  The search of the 
CINAHL database yielded 18 articles. Twelve of those articles did not meet the inclusion 
criteria, four were duplicates. In total, 86 articles met the inclusion criteria and were assigned a 
research level according to the Stetler, et al, (1998) levels of evidence.  This system assigns a 
level I rating to systematic reviews or meta-analysis and level II to individual experimental 
studies with randomization.  This system assigns a level III rating to quasi-experimental studies 
such as nonrandomized controlled single-group, pre-post, cohort, time series, or matched case-
controlled studies. A second reader was used to confirm levels of evidence.  The results of this 
study are shown in Table I. 
Much of the data in the systematic review articles were duplicated.  Other articles 
recommended a tiered approach to care beginning with conservative therapies and progressing to 
more aggressive therapies if symptoms of gastroesophageal reflux continued.  Systematic 
reviews dealt with one intervention or treatment that may or may not have been recommended. 
The conservative therapies or approaches to the treatment of gastroesophageal reflux in 
neonates and infants found in the articles reviewed are summarized below:   
 Parental reassurance is the easiest, least invasive treatment for infant regurgitation as 
symptoms usually decrease and disappear over time (Michail, 2007). 
 Prone or left-lateral positioning after feedings can reduce GERD in preterm infants but 
cannot be used without cardiac monitoring because of the risk of SIDS (Corvaglia, et al, 
(2007). 
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	 Faster gastric emptying can be seen with less liquid reflux and feeding on right side 
followed by change to left side after one hour (Van Wijk, et al, (2007). 
If the above initial conservative therapies are not effective in the treatment of GERD, the 
next approach identified in the articles is to use therapies related to a change in the feeding 
process. Effective feeding strategies are listed below: 
	 Small, slow, and more frequent feedings (with frequent burping) in a relaxed 
environment are helpful to infants with delayed gastric emptying (Brodsky & Carr, 
2006). 
	 Eliminating exposure to cow’s milk (Vandenplas, et al, 2005). 
	 Thickened feedings can reduce regurgitation events but commercially available products 
may be better than additives because of the balanced nutrition in commercial products 
(Vandenplas, et al, 2005). 
 Cornstarch can be used to thicken formula (Xinias, et al, 2005). 
 Cereal thickened formula (rice or oatmeal) can be used to reduce the frequency of 
regurgitation (Chao & Vandenplas, 2007). 
	 Hypoallergenic formula is supported in infants with recurrent emesis (Suwandhi, et al, 
2006). 
If initial conservative therapies are unsuccessful in relieving symptoms of 
gastroesophageal reflux, some alterations in feedings have been shown to help.  Brodsky & Carr 
(2006) identified that small, slow, and frequent feedings are helpful to infants with delayed 
gastric emptying.  Vandenplas, et al, (2005) recommend the elimination of exposure to cow’s 
milk as it may be efficacious for the reduction of symptoms of reflux.   
There is a large amount of data both for and against the use of thickened feedings to  
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reduce the symptoms of GERD.  In a study by Chao & Vandenplas (2007), cornstarch-thickened 
formula decreased the frequency of regurgitation and accelerated gastric emptying when 
compared to a more concentrated (125%) formula.  Chao & Vandenplas, in another study, also 
showed that cereal-thickened formula is significantly more efficacious than positioning therapy 
in decreasing the frequency of regurgitation (Chao & Vandenplas, 2007).  Xinias, et al, showed 
that a formula thickened with a specifically treated cornstarch reduced oesophageal reflux acid 
exposure and reduces the frequency of clinical symptoms (Xinias, et al, 2005).  Smaller volume 
feeds thickened with rice cereal can alleviate symptoms of GERD but feeds thickened with 
oatmeal can have the same results with less difficulty in defecation (Mascarenhas, et al, 2005). 
There are some studies looking at the effect of locust bean gum on gastroesophageal 
reflux. Miyazawa, et al (2007) showed a significant decrease in the number of regurgitation 
episodes with locust bean gum-thickened formula, although this study had a very small sample 
size and was non-randomized.  In a randomized trial with two different concentrations of locust 
bean gum-thickened formulas, there was a decrease in the number of regurgitation episodes 
(Miyazawa, et al 2004). Although this may be important data, locust bean gum thickened 
formulas are not currently available in the United States.  A study in 2007 showed that pre-
thickened AR (anti-regurgitation) formulas showed that this formula is more effective in 
reducing the reflux index when GERD is more severe (Moukarzel, et al, 2007).  Using a 
commercially available pre-thickened formula may be best because of nutritional concerns. 
Pharmacotherapy can be useful in the treatment of gastroesophageal reflux disease 
although it should not be used as a first step in the treatment of reflux symptoms (Guimaraes, et 
al (2006). Effective medications are listed below: 
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 Gaviscon Infant can be used as it increases the viscosity of feeds and reduces reflux (Del 
Buono, et al, 2005). 
 Ranitidine, an H2 receptor antagonist, is successful in reducing gastric acidity, but long
term gastric acid inhibitors can have sequelae (Tighe, et al, 2010). 
 Omeprazole, a proton pump inhibitor, can only be limitedly recommended as it is not 
well studied in neonates and infants (Bishop, et al, 2007).     
 Lansoprazole, a proton pump inhibitor, is well tolerated in neonates and infants but its 
efficacy is only established in children older than 1 year (Springer, et al, 2008).   
	 Esomeprazole, a proton pump inhibitor, does have acid suppressive effects in infants 
older than 1 month at a dose of 1mg/kg; systemic exposure in preterm infants and 
neonates at a dose of 0.5 mg/kg showed acid suppression but no effect on actual reflux 
events. This medication is only approved for use in children 1 year and older (Omari, et 
al, 2007). 
	 Cimetidine, a prokinetic agent, can be recommended limitedly for reduced regurgitation 
(Tighe, et al, 2010). 
Gaviscon Infant, which acts as a feed thickener, prevents reflux by increasing the 
viscosity of feeds. In a study by Del Buono, et al, (2005), patients given Gaviscon did show a 
significant difference in reflux height in the esophagus when compared to placebo.  It did not 
show a difference in the number of reflux events (Del Buono, et al, 2005).   
Tighe, et al, (2010) report that ranitidine, cimetidine, and famotidine have shown efficacy 
superior to placebo for symptom relief and oesophageal healing in many clinical trials (Tighe, et 
al, 2010). Omeprazole has not been extensively studied in children.  In a small study in children 
under 2 years, Bishop, et al, using pH studies to determine effectiveness, found the treatment 
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effective, with no serious complications or side effects.  The sample size was very small.  
Lansoprazole is well studied for use. In a randomized, controlled trial in infants older than 3 
months, the study group showed significant improvement in a shorter period of time when 
compared to the control group (Khoshoo and Dhume, 2008).  Springer, et al, were able to show 
an increase in the percentage of time that intragastric pH was above 3, 4, 5, and 6 (less acidic) 
over the 24 hour post-dose period when compared to baseline. In contradiction with the previous 
studies, in a very large, well designed study, Orenstein, et al, detected no difference in efficacy 
between lansoprazole and placebo for symptoms attributed to GERD in infants aged 1 to 12 
months. It is difficult to rule out the use of lansoprazole because it appears to have very few side 
effects. Further studies are recommended to determine its efficacy.
Esomeprazole has been recently studied in children.  In a study by Croxtall, et al, GERD 
symptoms improved significantly in children 1-11 years, but it was not studied in infants or 
children less than 1 year old (Croxtall, et al, 2008).  In another randomized trial, Gilger, et al, 
showed that esomeprazole was well tolerated and symptoms of GERD were significantly 
reduced during the active treatment (Gilger, et al, 2008).  Omari, et al, studied the effects of 
esomeprazole in infants 1 to 24 months old and found that it was well tolerated and showed acid 
suppression but not a decrease in the actual symptoms of GERD (Omari, et al, 2007).  In a study 
focused on preterm and term neonates, Omari, et al, showed that esomeprazole caused significant 
acid suppression but had no effect on the frequency, type, and extent of impedance-detected 
bolus reflux. This study had no placebo control group so it is difficult to say that the 
improvements were caused by the drug or that they would have simply occurred over time
(Omari, et al, 2009).  Esomeprazole may be useful to treat GERD although there may not be 
visible signs of improvement in terms of reflux episodes.     
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In one study by Canani, et al, long term use of gastric acid inhibitors including H2 
receptor antagonists and proton pump inhibitors was related to community acquired pneumonia 
and acute gastroenteritis. This is one reason that it is important to evaluate and re-evaluate the 
need for medications (Canani, et al, 2006). 
There are several treatments and medications that can be ruled out for use, or require 
further study in order to be used, in the treatment of GERD in infants: 
	 Cisapride cannot be recommended for use because of serious side effects.  This product 
has been removed from the market in the United States and is only available under 
compassionate care (MacLennan, et al, 2009).  
 Domperidone cannot be recommended for use as its efficacy for the treatment of GERD 
cannot be determined in the target population (Cresi, et al, 2008). 
 Metoclopramide has insufficient literature to support or oppose its use (Hibbs & Lorch, 
2006). 
 Nizatidine may have limited use.  Further studies should be done to determine the 
efficacy of the drug (Orentstein, et al, 2005). 
 Erithromycin efficacy has not been determined in neonates and infants (Tighe, et al, 
2010). 
 Baclofen has not been well studied in infants and needs further study (Omari, et al, 2006). 
 Bethanechol has insufficient evidence to recommend use (Tighe, et al, 2010). 
 Pantoprazole cannot be recommended as it is not studied in neonates and infants (Van 
Wijk, et al, 2007). 

 Antacids and sucralfate, both aluminum containing, should not be used in infants 

(Vandenplas, et al, 2005). 
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The most difficult aspect of prescribing medications in neonates and infants is that with
very little data in this age group, it is difficult to decide which medication to use to treat GERD.  
The medication chosen in the hospital setting appears to be driven more by physician preference 
than anything else. 
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Article 
Title/Author
Type of 
Article/
Study 
Participants Theme/Treatment Outcomes Level of 
Research/ 
Grade
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Pediatric Reflux: A 
Burp Gone Bad 
(2004, no author 
listed) 
Patient 
handout; no 
references 
listed 
Review article
focusing on
infants and 
older children
Focuses on feeding and 
formula types in 
infants; Focus on 
lifestyle changes, 
medications in older 
children 
No outcomes listed Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
…Maybe They
Can Be Avoided in 
Some Kids With 
Reflux (2008, no 
author listed)
Editorial 
within 
journal; short
synopsis of 
study as a 
child health 
alert
Infants with 
suspected 
GERD
Conservative therapy;
with no response, acid 
suppression therapy 
No outcomes listed Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
Managing gastro­
oesophageal reflux 
in infants (2009, no
author listed)
Review 
article 
Infants Treatment should be 
initiated if growth is 
affected.   
Dietary changes including 
eliminating exposure to cow’s milk 
even with breastfeeding if 
symptoms severe; Short term
nasogastric feeding for infants with 
poor weight gain; Thickening 
agents may be used to decrease 
incidents of regurgitation and 
increased weight gain; Positioning 
changes cannot be recommended; 
Gaviscon can be recommended with 
limitations; Cimetidine and 
Famotidine can be recommended 
limitedly for reduced regurgitation; 
Omeprazole can be used to reduce 
gastric acidity, acid exposure and 
number and duration of gastro­
oesophageal reflux episodes. 
Level 
I/Grade B
Review of 
Randomized 
Controlled 
Trials for 
Recommendatio 
ns 
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses/  
Recommend 
for use 
in review 
Developmental 
Pharmacokinetics 
and 
Pharmacodynamics
of Nizatidine 
(2004, Abdel-
Rahman, et al) 
Non-
randomized 
trial; open-
label, single 
dose or 
multiple dose 
trial 
Children aged 
5 days to 18 
years and 
adults aged 18­
50 years 
Nizatidine of various 
dosages. 
The biodisposition of Nizatidine in 
children is similar to adults. 
Response after a comparable
weight-based dose is equal and 
potentially greater in children. 
Level 
III/Grade 
B 
This study did 
not test the 
response but the 
disposition of the 
drug to determine 
dosage. Limited 
usage without
trials to discuss 
efficacy. 
Not without 
additional 
trials to 
discuss 
efficacy of 
Nizatidine 
for 
treatment of 
GERD
Infant Formulas 
Thickened with 
Carob Bean Gum
Causing False-
Positive 
Galactomannan 
Test Reactivity 
(2008, Aceti, et al) 
Editorial 
Comment 
Hospitalized 
children 
Children on formulas 
thickened with carob 
bean gum can have 
false-positive 
Galactomannan test. 
No outcomes listed Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
Protein Content 
and Fortification of 
Human Milk 
Influence 
Gastroesophageal 
Reflux in Preterm
Infants (2009, 
Aceti, et al)
Case control 
study 
17 preterm
newborns fed 
naïve and 
fortified human 
milk 
Human Milk 
fortification can 
increase the protein 
content in human milk 
and influence 
gastroesophageal reflux 
An individualized fortification, 
based on the analysis of the 
composition of naïve human milk 
could optimize both nutrient intake 
and feeding intolerance 
Level 
III/Grade 
B 
Statistically
significant in 
reflux episodes 
with increased 
protein content in 
fortified human 
milk (p<0.05)
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses/  
Recommend 
for use 
in review 
Anti-reflux or
Anti-regurgitation 
Milk Products for 
Infants and Young
Children: a 
Commentary by
the ESPGHAN 
Committee on 
Nutrition (2004, 
Agostini, C. on 
behalf of 
ESPGHAN 
Committee of 
Nutrition)
Editorial 
comment 
Infants and 
young children 
Formula with
thickening agents to 
decrease regurgitation 
and reflux
No outcomes noted Level 
VI/Grade 
D 
Formulas with
thickening agents 
should not be
used 
indiscriminately.
No 
The Reflex to Treat 
Reflux – Let’s be 
Conservative 
Regarding 
Gastroesophageal 
Reflux (GER)! 
(2008, Balistreri, 
W.F.) 
Editorial 
comment 
Infants and 
Children 
Conservative therapy
for GERD should be 
used in infants. 
Medications may be 
overprescribed in this 
population
No outcomes noted Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
Lack of Age-
Appropriate RCTs 
Make Evidence-
Based Treatment 
Difficult (2005, 
Bell, A. L.) 
Editorial 
comment 
Infants Treatment with 
medications if 
conservative therapy
fails is not well 
supported with clinical 
trials 
No outcomes noted Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Gastro­
oesophageal Reflux 
Disease in Preterm
Infants: Current 
Management and 
Diagnostic 
Dilemmas (2009, 
Birch & Newell) 
Review 
Article 
Preterm Infants Conservative therapy
for treatment should be 
utilized before moving 
to more advanced 
treatments
Prone or left-lateral positioning 
reduces GORD in preterm infants, 
should only be used in hospitalized 
infants with cardio respiratory
monitoring.  Evidence is limited for 
the beneficial effects of thickeners. 
Carob-based thickeners reduce non­
acid reflux in older infants. No 
good evidence for the use of 
Erithromycin.  Ranitidine is
successful in reducing gastric 
acidity. Cimetidine not 
recommended in preterm infants.  
There is no evidence that Proton 
pump inhibitors are more effective 
than ranitidine in treating GORD 
and their safety is not well studied.  
Domperidone not recommended in 
preterm infants. 
Level 
I/Grade 
B 
Review of trials 
for preterm
infants; 
Suggested 
management 
strategy from 
conservative 
therapy to more 
advanced 
treatments. 
Yes
Omeprazole for 
Gastroesophageal 
Reflux Disease in 
the First 2 Years of 
Life: A Dose 
Finding Study with 
Dual Channel pH 
Monitoring (2007, 
Bishop, et al) 
Prospective 
Dose-finding 
study 
Children under 
2 years of age 
Treatment with 
Omeprazole
Omeprazole is an effective 
treatment for gastroesophageal 
reflux disease in children younger 
than 2 (p<0.05) although sample 
size was small (10 children). 
Level 
III/Grade 
B 
Used pH studies 
to determine 
effectiveness, no 
serious 
complications or 
side effects. 
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses  
Recommend 
for use 
in review 
Extraesophageal 
Reflux in Children 
(2006, Brodsky and 
Carr)
Review 
article 
Children 
(infants to 
adolescents)
Conservative 
treatments including 
environmental 
exposures and feeding 
alterations should be 
considered before 
medications 
Infants: Soy, partially hydrolyzed, 
and elemental formulas can be 
helpful. Small, slow, and frequent 
feedings in a relaxed environment 
are helpful to infants with delayed 
gastric emptying.  Thickening of 
formula should be avoided.
Children aged 2-11 years: Spicy, 
acidic, caffeinated and fatty foods 
should be avoided.  Carbonated 
beverages should be avoided.   
Little support for medications in 
children noted.
Level 
I/Grade 
B 
Review article.  
Studies not cited 
within article. 
Yes/Limited 
Therapy with 
Gastric Acidity 
Inhibitors Increases 
the Risk of Acute 
Gastroenteritis and 
Community-
Acquired 
Pneumonia in 
Children (2006, 
Canani, et al) 
Non-
randomized 
control trial
Children aged 
4-36 months 
Treatment of 
gastroesophageal reflux 
with gastric acid 
inhibitors. 
The use of gastric acid inhibitors is 
associated with an increased risk of 
acute gastroenteritis and 
community-acquired pneumonia in 
children with GERD.
Level 
III/Grade 
B 
Large sample
size. Low p-
values for 
statistical 
significance. Use 
caution when 
prescribing 
gastric acid 
inhibitors. 
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Comparison of the 
Effect of a 
Cornstarch 
thickened Formula 
and Strengthened 
Regular Formula 
on Regurgitation, 
Gastric Emptying 
and Weight Gain in 
Infantile 
Regurgitation 
(2007, Chao & 
Vandenplas) 
Prospective 
Randomized 
Trial – infant 
used as own 
control – for 
two different 
interventions
Infants with 
regurgitation/
vomiting > 3 
times per day
Cornstarch thickened 
formula vs. 25%
strengthened regular 
infant formula (five 
scoops instead of 4 
scoops to 120mL of 
water).
Cornstarch-thickened formula 
feeding decreases the frequency of 
regurgitation/vomiting, provides 
better body weight gain and has an 
accelerated gastric emptying in 
comparison to a 25% strengthened 
regular formula in infants with 
regurgitation.
Level 
II/Grade 
B 
Fairly large 
sample size, 
focused on 
infants, with low 
p values for 
statistical 
significance. 
Randomized trial 
using infant as
own control.
Yes
Effect of Cereal-
Thickened Formula 
and Upright 
Positioning on
Regurgitation, 
Gastric Emptying, 
and Weight Gain in 
Infants with 
Regurgitation 
(2007, Chao & 
Vandenplas) 
Prospective 
randomized 
trial 
Infants 2 to 6 
months of age 
with 
regurgitation or 
vomiting at 
least 3 times 
per day 
Cereal-thickened 
formula versus 
postprandial upright
position for 90 minutes. 
Cereal-thickened formula is
significantly more efficacious than 
postural therapy in decreasing the 
frequency of regurgitation. Cereal 
thickened formula also results in an 
increased caloric intake 
(approximately 25%) related to 
increased gain in weight and length 
in comparison with regular formula 
and positioning therapy.
Level 
II/Grade 
B 
Fairly large 
sample size.  
Focused on 
infants. 
Statistically
significant 
results. 
Yes
Patience is a Virtue 
in the Management 
of 
Gastroesophageal 
Reflux (2009,
Clark & Spitzer) 
Editorial 
comment 
Children Conservative therapies 
often decrease 
symptoms of reflux – 
more advanced 
therapies may not be 
necessary.
No outcomes noted Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Starch Thickening 
of Human Milk is 
Ineffective in 
Reducing the 
Gastroesophageal 
Reflux in Preterm
Infants: A 
crossover Study
Using Intraluminal 
Impedance (2006, 
Corvaglia, et al) 
Crossover 
Trial 
Preterm infants Thickening of fortified 
human milk by 
precooked starch. 
Thickening human milk by
precooked starch is ineffective in 
reducing gastroesophageal reflux in 
premature infants 
Level 
III/Grade 
B 
Small sample 
size. Because of 
risk of 
necrotizing 
enterocolitis with 
thickened milk in 
pre-term infants, 
would not 
recommend 
starch thickening 
Yes
The Effect of Body
Positioning on
Gastroesophageal 
Reflux in 
Premature Infants:  
Evaluation by
Combined 
Impedance and pH 
Monitoring (2007, 
Corvaglia, et al) 
Non-
randomized, 
using subject 
as their own 
control
Preterm infants Positioning in the prone 
or left lateral position 
and its effect on 
gastroesophageal reflux 
Placing premature infants in the 
prone or left lateral position in the 
postprandial period is a simple 
intervention to limit GER.
Level 
III/Grade 
B 
Small sample 
size but 
statistically
significant 
results. Non­
invasive 
intervention. 
Yes
Short-term Effect 
of Domperidone on 
Gastroesophageal 
Reflux in 
Newborns 
Assessed by
Combined 
Intraluminal 
Impedance and pH 
Monitoring (2008, 
Cresi, et al)
Randomized 
controlled 
trial 
Term and 
Preterm
neonates 
Use of Domperidone to 
decrease the number of 
reflux episodes 
There was a paradoxical increase in 
the number of GER episodes in the 
treatment group.  This treatment 
may not be efficacious in this age 
bracket. 
Level 
II/Grade 
B 
Small sample 
size with 
statistically
significant 
results. Would 
not use this 
treatment in this 
age group as 
more studies are 
needed. 
Yes
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Gaviscon for 
Gastro­
oesophageal Reflux 
in Infants: a Poorly
Effective 
Treatment? (2006, 
Cresi, et al)
Editorial 
comment 
Infants Gaviscon for reflux 
treatment 
No outcomes noted Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
Lansoprazole In 
the Treatment of 
Gastro­
0oesophageal 
Reflux Disease in 
Children and 
Adolescents (2005, 
Croom & Scott) 
Open-label, 
uncontrolled
trial 
Children aged 
1-11 years.
Adolescents 
aged 12-17
years. 
Drug treatment (proton 
pump inhibitor) that 
inhibits gastric acid 
secretion
The effectiveness and tolerability of 
Lansoprazole has been established 
in pediatric patients aged 1-17 years 
for short-term treatment of 
symptomatic GORD and erosive 
oesophagitis.
Level 
III/Grade 
B 
Does not look at 
infants and 
children less than 
1 year of age.  
Not a 
randomized-
controlled trial. 
Yes/Limited 
to children 1 
year old or 
older 
Esomeprazole in 
Gastroesophageal 
Reflux Disease in 
Children and 
Adolescents (2008, 
Croxtall, et al) 
Randomized, 
double-blind,
multicenter 
trial 
Children aged 
1-11 years. 
Adolescents 
aged 12-17
years. 
Drug treatment (proton 
pump inhibitor) that 
inhibits gastric acid 
secretion
GERD symptoms significantly
improved with Esomeprazole in 
children aged 1-11 years and 
adolescents aged 12-17 years in.  
Esomeprazole was generally well 
tolerated in both children and 
adolescents.
Level 
II/Grade 
B 
Does not look at 
infants and 
children less than 
1 year of age.   
Yes/Limited 
to children 1 
year old or 
greater.
Effect of Gaviscon 
Infant on Gastro­
oesophageal Reflux 
in Infants Assessed 
by Combined
Intraluminal 
Impedance/pH
(2005, Del Buono, 
et al) 
Randomized, 
placebo 
controlled, 
double blind
study 
Children under 
12 months of 
age. 
The influence of 
Gaviscon Infant on 
Gastro-oesophageal 
Reflux in infants 
Results showed a marginal but 
significant difference between 
Gaviscon Infant and placebo in 
average reflux height.  The
treatment did not show a significant 
difference in median number of 
reflux events per hour, acid reflux 
events per hour, minimum distal or 
proximal pH, total acid clearance 
time per hour and total reflux 
duration per hour between treatment 
and placebo.
Level 
II/Grade 
B 
Good study 
design, small 
number of 
subjects. Does 
not appear to be a 
perceived clinical 
benefit to the 
treatment’s use.
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Does Treating Editorial Infants and Relationship between No outcomes noted Level No No 
Gastroesophageal Comment children proton pump inhibitor VI/Grade recommendation 
Reflux Cause or H2 blocker use for D for use 
Pneumonia? (2005, the treatment of GER 
Federico, M) and community-
acquired pneumonia 
Systematic Systematic Infants Review to evaluate the There is insufficient evidence to Level Review of Yes
Review: Proton Review efficacy and safety of determine the role of proton pump I/Grade randomized 
Pump Inhibitors for proton pump inhibitors inhibitor therapy for treatment of A controlled trials. 
the Treatment of for the treatment of GERD in infants. Further trials are 
Gastroesophageal GERD in infants. needed addressing both safety and 
Reflux in Infants efficacy of proton pump inhibitors 
(2008, in infants. 
Gieruszczak-
Bialek, et al)
Safety and Multicenter, Children aged Treatment with In children with endoscopically Level Well designed Yes/Limited 
Tolerability of randomized, 1 to 11 years. Esomeprazole for proved GERD, Esomeprazole was II/Grade study. Large 
Esomeprazole in uncontrolled, gastroesophageal reflux generally well tolerated.  Frequency B sample size.  
Children with double-blind disease and severity of GERD-related Low P values for 
Gastroesophageal study. symptoms significantly reduced statistical 
Reflux Disease during active treatment period. significance. 
(2008, Gilger, et al) 
Gastroesophageal Review Children Do treatments for Treatments for pediatric GERD are Level Review article Yes/Limited 
Reflux Disease: article gastroesophageal reflux based on the clinical indications of the I/Grade with current data. 
Could Intervention disease in children specific child with GERD and range B No specific 
in Childhood 
Reduce the Risk of 
Later 
Complications? 
reduce the risk of later 
complications in 
adulthood? 
from conservative measures 
(positioning, formula changes) to
pharmacotherapy to surgery.  Proton
pump inhibitors are safe, effective, and 
due to their superiority in resolving acid
reference to 
infants. 
(2004, Gold, B. D.) related disease, could be appropriate 
interventions in GERD occurring in 
childhood to successfully prevent long 
term sequelae.
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Treatment of 
Gastroesophageal 
Reflux Disease 
(2006, Guimaraes, 
et al) 
Review 
article 
Infants and 
Children 
Treatment of 
gastroesophageal reflux 
disease with emphasis 
on pharmacological 
aspects.
Left lateral and prone positioning
should only be considered in infants 
if the risks related to GERD 
outweigh the risk of sudden infant 
death syndrome.  There is no 
benefit to inclined positions.  
Thickened formulas may reduce 
clinical symptoms but not actual 
reflux in the esophagus.  Avoiding
spicy, caffeinated foods and 
chocolate is recommended in older 
children. H2 receptor antagonists 
and proton pump inhibitors have 
some support for use.  
Level 
I/Grade 
A 
Review article of 
controlled and 
randomized trials 
and review 
articles.
Yes
Gastroesophageal 
Reflux and 
Prokinetic Agents 
(2005, Hammer, 
D.) 
Review 
article 
Preterm and 
term infants 
Treatment of GER with 
prokinetic agents. 
Non-pharmacologic agents are the 
first step in treating GER including 
positioning and feeding 
interventions. Bethanechol is not 
recommended for treatment.  
Erythromycin is not recommended 
for treatment. Metoclopromide can 
be recommended for use.  
Level 
I/Grade 
B 
Review article
looking at 
preterm and term
infants. 
Yes
Talk is Cheap, 
Often Effective:  
Symptoms in
Infants Often 
Respond to Non­
pharmacologic 
Measures (2008, 
Hassall, E.) 
Editorial 
comment 
Infants Non-pharmacologic 
treatment of 
gastroesophageal reflux 
No outcomes noted Level 
VI/Grade 
D 
No 
recommendation 
for use 
No 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
26 
 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Characteristics of 
Children Receiving 
Proton Pump
Inhibitors 
Continuously for 
Up to 11 Years 
Duration (2007, 
Hassall, et al)
Retrospective 
cohort study
Children aged 
less than 1 year 
to 17 years old.
Long-term treatment 
with proton pump
inhibitors for 
gastroesophageal reflux 
disease.
Children with long term proton 
pump inhibitor use have few 
adverse reactions and 
discontinuation of the drug is 
seldom indicated.  Preliminary data 
suggest that proton pump inhibitors 
may be efficacious and safe for 
continuous use for up to 11 years 
duration in children.
Level 
III/Grade 
B 
Cohort study 
with large sample
size.
Domperidone 
Versus Cisapride in 
the Treatment of 
Infant 
Regurgitation and 
Increased Acid
Gastro­
oesophageal 
Reflux: A Pilot 
Study (2009, 
Hegar, et al)
Investigator-
blinded, 
prospective 
comparative 
trial. 
Infants 
regurgitating 
more than 4
times per day
for more than 2 
weeks after 
conservative 
treatment 
failure. 
Prokinetic therapy for 
the treatment of 
gastroesophageal reflux 
symptoms.
The frequency of regurgitation 
decreased in both groups although 
more rapidly in the Cisapride group.  
The decrease in regurgitation was 
still significant after 1 month.  The 
natural decrease in the incidence of 
regurgitation induced by age should 
also be considered. 
Level 
II/Grade 
B 
Pilot study with 
small sample 
size. Blinded, 
prospective, 
comparative trial 
with no controls. 
Yes/Limited 
Natural Evolution 
of Infantile 
Regurgitation 
Versus the Efficacy
of Thickened 
Formula (2008, 
Hegar, et al)
Prospective, 
blinded, 
randomized 
1-month 
intervention 
trial 
Healthy, term-
born, formula-
fed infants 
aged 1 to 3 
months. 
Therapy of parental 
reassurance in
combination with 
standard infant 
formula, 5 grams of 
rice cereal added to 
100mL standard 
formula, or formula 
manufactured with 
bean gum as a 
thickening agent. 
Thickening of formula decreases 
regurgitation, but not significantly. 
Parental reassurance remains the 
cornerstone of the treatment of 
infant regurgitation.
Level 
II/Grade 
B 
Sample size of 60 
infants. 
Randomized trial 
with statistically 
significant 
results. 
Yes
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 Table I Article Type of Participants Theme/Treatment Outcomes Level of Study strengths/ Recommend 
Title/Author Article/Study Research Weaknesses for use 
/Grade in review 
Pharmacokinetics Subanalysis 8 toddlers Treatment with Lansoprazole displays Level Very small Yes/Limited 
and of 8 toddlers between 13 and Lansoprazole increased pharmacokinetic and III/Grade sample size.  
Pharmacodynamics who 24 months. if symptomatic after 2 pharmacodynamic parameters in B Non-randomized 
of Lansoprazole in participated weeks of treatment children between 13 and 24 months trial. 
Children 13 to 24 in a phase I/II of age that are similar to those 
Months Old With open-label, results observed in older children as 
Gastroesophageal multicenter well as adults.  Further studies are 
Reflux Disease US study needed to confirm results.
(2007, Heyman, et 
al) 
Metoclopramide Systematic Infants Treatment with 11 prospective trials, 5 were Level Inconclusive Yes
for the Treatment Review Metoclopramide for randomized, blinded clinical trials.  I/Grade recommendation 
of gastroesophageal reflux The current literature is insufficient A for usage. 
Gastroesophageal disease. to either support or oppose the use Further trials 
Reflux Disease in of Metoclopramide for needed. 
Infants: A gastroesophageal reflux disease in 
Systematic Review infants. 
(2006, Hibbs & 
Lorch) 
The Effect of Systematic Infants Effect of feed Thickened food is only moderately Level Used Yes/Limited 
Thickened-Feed Review with thickeners on effective in treating I/Grade Randomized 
Interventions on meta-analysis gastroesophageal reflux gastroesophageal reflux in term A Controlled Trials. 
Gastroesophageal disease. infants. The data did not allow the 
Reflux in Infants: authors to conclude whether any
Systematic Review particular thickening agent is 
and Meta-analysis definitely more effective than 
of Randomized, another. 
Controlled Trials 
(2008, Horvath, et 
al) 
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Feed Thickener for 
Newborn Infants 
With Gastro­
oesophageal Reflux 
(2009, Huang, et 
al) 
Systematic 
Review 
Newborn 
Infants 
The use of feed 
thickeners in reducing 
signs and symptoms of 
GOR, acid episodes on 
pH monitoring and 
histological evidence of 
oesophagitis.
No suitable studies were found for
inclusion in the review. 
Level 
I/Grade 
A 
Reviewed 
randomized, 
controlled trials. 
Yes/Limited 
Gastroesophageal 
Reflux in Preterm
Infants: How Acid 
Should It Be? 
(2008, Indrio, et al) 
Editorial 
comment 
Preterm Infants Effect of proton pump
inhibitors on 
gastroesophageal 
reflux. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
Update on Drugs 
for Gastro­
oesophageal Reflux 
Disease (2007, 
Keady, S.) 
Review 
article 
Infants, 
children and 
adolescents
Review of management 
techniques to treat 
gastro-oesophageal 
reflux disease. 
Antacids can be used as first line 
medication although there are not 
long-term effects.  Gaviscon Infant 
can be used. Domperidone shows 
very little efficacy.  Erithromycin 
efficacy in neonates and infants has 
not been supported by clinical trials.  
Metoclopromide has limited use as 
adverse effects are severe.  The 
product license for Cisapride has 
been withdrawn. Ranitidine has 
efficacy in mild oesophagitis.  
Proton pump inhibitors such as 
Lansoprazole and Omeprazole show 
benefit but children seem to 
metabolize them quicker so a daily
dose regimen may be necessary.
Lack of child suitable formulations 
can limit their use. 
Level 
I/Grade 
B 
Review did not 
include only 
randomized 
controlled trials. 
Yes
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Clinical Response 
to 2 Dosing
Regimens of 
Lansoprazole in 
Infants With 
Gastroesophageal 
Reflux (2008,
Khoshoo and
Dhume) 
Randomized 
Controlled 
Trial 
Infants older 
than 3 months
born at term. 
To determine the 
clinical efficacy of 2 
dosing regimens of 
Lansoprazole in infants 
with GERD.
The two different doses had better 
results for infants than those in the 
control group.  The group with the 
twice daily doses showed 
significant improvement in a shorter 
period of time.  There may be a 
faster onset of symptom
improvement but eventually there 
was no difference between the two 
doses overall. 
Level 
II/Grade 
B 
Randomized 
controlled trial.  
66 participants in 
the study,
reasonable 
sample size.
Yes
Soothing Your 
Breastfed Baby
With Reflux (2009, 
Kombol, P.)
Parent 
Handout
Breastfed 
infants up to 1 
year of age
Feeding interventions 
to deal with 
gastroesophageal 
reflux. 
No outcomes noted  Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
Treating GER in 
Children Younger 
Than Two Years 
(2005, Kripke, C.) 
Editorial 
comment 
Children 
younger than 2 
years. 
Conservative therapy
for the treatment of 
GER. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
FDA Approves 
Nexium for Use in 
Children Ages 1-11 
Years (2008, Lang, 
L.) 
Bulletin Children aged 
1-11 years.
Treatment approved for
use in gastroesophageal 
reflux disease. 
No outcome noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Use of Medications 
for 
Gastroesophageal 
Reflux at 
Discharge Among 
Extremely Low 
Birth Weight 
Infants (2008, 
Malcolm, et al) 
Retrospective 
cohort 
analysis 
Extremely low 
birth weight 
infants at 
corrected ages
of 18 to 22
months. 
Medication usage in the 
treatment of 
gastroesophageal reflux 
disease and the effect 
on growth or 
development at the 
time of follow-up 
evaluations. 
Use of antireflux medications at the 
time of discharge for extremely low 
birth weight infants does not seem
to have effects on growth or
development.  Medications included 
were antacids and H2 receptor 
antagonists. 
Level 
III/Grade 
B 
Large sample
size. Medication 
types not broken 
down into
groups.
Yes
Drugs for the 
Treatment of 
Gastro­
oesophageal 
Reflux: In Search 
of Clear Evidence-
based Indications 
(2007, Marchetti, 
et al) 
Editorial 
comment 
Infants Drugs for the treatment 
of gastroesophageal 
reflux disease. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
Gastroesophageal 
Reflux in Preterm
Infants: Is 
Positioning the 
Answer? (2007, 
Martin, et al) 
Editorial 
comment 
Preterm Infants Positioning as the 
treatment for 
gastroesophageal 
reflux. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
Difficulty in 
Defecation in 
Infants with 
Gastroesophageal 
Reflux Treated 
with Smaller 
Volume Feeds 
Thickened with 
Rice Cereal (2005, 
Mascarenhas, et al) 
Non-
randomized, 
case control 
study.
Full-term, 
neurologically
intact infants 
less than 5 
months of age. 
Treatment of rice cereal 
thickened, small 
volume feeds for 
gastroesophageal reflux 
and its relation to 
difficulty with 
defecation. 
Smaller volume feeds thickened 
with rice cereal was effective in 
alleviating symptoms of GER but 
about one third of the infants had 
difficulty with defecation.  
Changing rice to oatmeal resulted in 
partial or complete improvement in 
defecation difficulty in about 70%
of these infants without causing a 
change in symptoms of 
gastroesophageal reflux. 
Level 
I/Grade 
B 
Study design 
limited.  The 
measurement of 
symptoms of 
gastroesophageal 
reflux was likely
inadequate. 
Yes/Limited 
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Cisapride 
Treatment for 
Gastro-
Oesophageal 
Reflux in Children 
(2009, MacLennan, 
et al) 
Systematic 
Review 
Children 
diagnosed with
gastro­
oesophageal 
reflux 
Does Cisapride reduce 
symptoms of gastro­
oesophageal reflux? 
Ten trials in total met the inclusion 
criteria for this systematic review.  
There was no clear evidence that 
Cisapride reduces symptoms of 
gastro-oesophageal reflux. 
Level 
I/Grade 
A 
Review used 
randomized 
controlled trials 
for review. 
Cisapride not 
recommended for 
use and treatment 
is limited to 
patients treated 
within a clinical 
trial program.
Yes
Gastroesophageal 
Reflux (2007,
Michail, S.) 
Review 
article 
Pediatric 
population
Appropriate therapies 
for gastroesophageal 
reflux disease. 
Reassurance and educating the 
family in an otherwise healthy
infant can be the only intervention 
in some.  Lifestyle changes can be 
helpful for children with mild 
disease. Feeding interventions 
would be the next intervention for 
moderate disease.  Prone 
positioning can be used only when 
there is no risk of death from SIDS.  
Antacids can be used for short-term
therapy and relieve of symptoms.  
H2 receptor antagonists have 
demonstrated efficacy esophagitis 
but not as well as proton pump
inhibitors.  Surface agents should be 
used with caution. 
Level 
I/Grade 
B 
Review article.  
Not limited to 
randomized 
controlled trial 
review.
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Effect of Formula 
Thickened with 
Reduced 
Concentration of 
Locust Bean Gum
on 
Gastroesophageal 
Reflux (2007,
Miyazawa, et al) 
Non 
randomized 
case-control 
study.
Infants less 
than 2 months
old who had 
three or more
episodes of 
regurgitation or 
vomiting per 
day.
Treatment with locust 
bean gum thickened 
formula for 
gastroesophageal reflux 
disease.
The median number of regurgitation 
episodes decreased significantly 
(p=o.ooo48) with the thickened 
formula.  No significant difference 
was evident in feeding volume and 
time, body weight gain, or gastric 
emptying rate between thickened 
and non-thickened formula. 
Level 
III/Grade 
B 
Small study
number (20), but 
used infants as 
their own control.
Yes
Effect of Locust 
Bean Gum in Anti­
regurgitant Milk on 
the Regurgitation 
in uncomplicated 
Gastroesophageal 
Reflux (2004,
Miyazawa, et al) 
Randomized, 
controlled 
crossover 
trial 
Infants with 
daily 
regurgitation 
but no other 
medical 
problems 
Effect of different 
concentrations of locust 
bean gum in anti­
regurgitant milk on 
gastroesophageal 
reflux. 
Both concentrations of AR formulas 
decreased the number of 
regurgitation episodes by about 
50%. The decreased concentration 
of locust bean gum may be easier 
for the infant to suck through the 
nipple.
Level 
II/Grade 
B 
Small sample 
size (30) but a 
randomized 
controlled 
crossover trial. 
Yes
Effect of Formula 
Thickened with 
Locust Bean Gum
on Gastric 
Emptying in
Infants (2006, 
Miyazawa, et al) 
Randomized 
controlled 
trial 
Infants with 
three or more
episodes of 
regurgitation 
per day without 
other major 
medical 
problems. 
Two different formulas 
with two different 
concentrations of locust 
bean gum compared to 
a control formula 
without locust bean 
gum and their effect on 
gastric emptying.
Thickened formula with locust bean 
gum slowed gastric emptying more 
than one with a reduced 
concentration of this thickening 
agent and more than a formula 
without a thickening agent.
However, thickened formulas 
reduced the number of regurgitation 
episodes after feeding, without 
causing any complications. 
Level 
II/Grade 
B 
Randomized, 
controlled trial 
with fair sample 
size. Formulas 
thickened with 
locust bean gum
are not readily 
available in the 
United States. 
Yes/Limited  
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Effects of a 
Prethickened 
Formula on 
Esophageal pH and 
Gastric Emptying 
of Infants with 
GER (2007, 
Moukarzel, et al) 
Randomized 
controlled 
trial 
74 healthy
infants less 
than 6 months
old with GER.
Prethickened formula 
used for infants with 
GER and their effect on 
gastric pH and gastric 
emptying.  A reflux 
index score was used to 
measure severity of 
reflux disease. 
This studies was able to show a 
significant (p<0.01) improvement in 
the reflux index of infants who 
received the AR (anti-regurgitation, 
pre-thickened) formula.  There was 
also significantly faster clearance 
from the esophagus of AR than 
regular formula which was a 
difference of almost one minute.  
The longest reflux episode of the 
AR fed group was significantly
shorter than the longest reflux 
episode of the regular formula fed 
group.  The study suggests that AR 
formula is more effective in
reducing the reflux index when 
GER is more severe.
 Level 
II/Grade 
B 
Randomized 
controlled trial 
with moderate
sample size.  
Excellent P 
values for 
statistical 
significance. 
Yes
Gastroesophageal 
Reflux in Infants: 
Can a Simple Left 
Side Positioning 
Strategy Help This 
Diagnostic and 
Therapeutic 
Conundrum? 
(2008, Omari, T.) 
Review 
Article 
Preterm and 
term infants 
from 0-6 
months of age. 
Left-sided positioning 
as a non-
pharmacological 
approach to the 
treatment of GER 
related symptoms. 
Left side positioning will reduce the 
number of reflux events in infants 
and is likely to complement
standard proton pump inhibitor 
therapy.  It has not been proven that 
left side positioning will reduce 
symptoms due to gastroesophageal 
reflux in infants.  Left side 
positioning can increase the risk of 
SIDS and should only be used for 
short periods of time (2 hours post 
prandial) and not overnight when an 
infant is unobserved. 
Level 
I/Grade 
B 
Review article
focusing on
position in the 
treatment.  Not a 
systematic 
review.
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Pharmacokinetics 
and Acid-
suppressive Effects 
of Esomeprazole in 
Infants 1-24 
Months Old with 
Symptoms of
Gastroesophageal 
Reflux Disease 
(2007, Omari, et 
al). 
Single-blind, 
randomized, 
parallel-
group study 
50 infants 1 to
24 months old 
with symptoms 
of GERD 
Treatment with 
esomeprazole and its 
effect on GERD
Oral treatment with esomeprazole 
0.25 mg/kg and 1 mg/kg was well 
tolerated and provided dose-related 
acid suppression, dose-related 
exposure to esomeprazole and 
decreased esophageal acid exposure 
in infants. The dosage of 1 mg/kg 
provided the most effective acid 
suppression, normalizing 
esophageal acid exposure in this 
group of patients.  The effect of 
esomeprazole on symptoms of 
GERD in the infants participating in 
the trial were inconclusive because 
there were no obvious changes in 
vomiting, choking/gagging and 
irritability/crying symptom scores 
during 1 week of treatment. 
Level 
II/Grade 
B 
Randomized 
study with good 
sample size.  No 
placebo control 
within study. 
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Pharmacodynamics
and Systemic
Exposure of 
Esomeprazole in 
Preterm Infants and 
Term Neonates 
with 
Gastroesophageal 
Reflux Disease 
(2009, Omari, et 
al). 
Open-label 
trial 
Preterm infants 
and term
neonates aged 
< 1 month term
age. 
Treatment with 
esomeprazole for 
GERD
Esomeprazole 0.5 mg/kg given once 
daily showed significant acid 
suppression but had no effect on the 
frequency, type, and extent of 
impedance-detected bolus reflux.  
Despite increased systemic
exposure, treatment with 
esomeprazole was well tolerated, 
and significant acid suppression was 
apparent, indicating that the chosen 
dosage of 0.5 mg/kg once daily is 
appropriate in the preterm infant 
and term neonate population.  The 
number of symptoms overall, as 
well as individual symptoms of 
gagging and irritability/crying, were 
significantly reduced on therapy.
Level 
III/Grade 
B 
No placebo 
control group.  
Difficult to say 
that treatment
caused 
improvements 
versus 
improvement that 
might have 
occurred over 
time. Good 
sample size.
Yes
Effect of Baclofen 
on Esophagogastric 
Motility and 
Gastroesophageal 
Reflux in Children 
with 
Gastroesophageal 
Reflux Disease: A 
Randomized 
Controlled Trial 
(2006, Omari, et 
al). 
Randomized 
Controlled 
Trial 
Children aged 
2.6 years to 
17.4 years.
Trial to look at the 
effects of Baclofen on 
motility and 
gastroesophageal 
reflux. 
Baclofen significantly reduced the 
rate of triggering of transient lower 
esophageal sphincter relaxation 
(TLESR) and GER but did not 
reduce the rate of swallowing, the 
pattern of peristalsis or the 
magnitude of lower esophageal 
sphincter pressure compared with 
placebo. Baclofen reduced the 
triggering of TLESRs in children 
and this was associated with a 
reduced number of GER episodes. 
Baclofen also increases gastric 
emptying.  
Level 
II/Grade 
B 
Randomized 
controlled trial.  
30 children 
enrolled. Does 
not specifically 
study the effects 
on infants. This 
study did not 
address how well 
long term therapy
with Baclofen 
would be 
tolerated in 
children. 
Yes/Limited 
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Nizatidine for the 
Treatment of 
Pediatric 
Gastroesophageal 
Reflux Symptoms: 
An Open-Label, 
Multiple-Dose, 
Randomized, 
Multicenter 
Clinical Trial in 
210 Children 
(2005, Orenstein, 
et al). 
Randomized, 
parallel 
group, open-
label, 
multiple-
dose, 
multicenter 
study.
Children aged 
5 days through 
12 years and 13 
years through 
18 years. 
Treatment with 
Nizatidine in various 
doses and formulations 
for gastroesophageal 
reflux disease.  
Tolerability of nizatidine is 
supported in the current study. 8 
weeks of treatment with nizatidine 
were accompanied by complete 
resolution of all reflux symptoms in 
nearly one third of the children in 
the treatment groups.  There was an 
overall improvement in symptoms 
and a decrease in antacid use in the 
pediatric study population.
Formulation did not appear to alter 
tolerability or effectiveness. 
Level 
II/Grade 
B 
Open label 
design. Large 
sample size.  
Multiple dosing 
and formulation 
groups modulate 
the power of the 
study.
Yes/Limited 
Infants and Proton 
Pump Inhibitors: 
Tribulations, No 
Trials (2007, 
Orenstein & 
Hassall).
Editorial 
Comment/ 
Expert 
opinion
Infants Treatment with proton 
pump inhibitors for the 
treatment of 
gastroesophageal 
reflux. 
No outcome noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
Multicenter, 
Double-Blind,
Randomized, 
Placebo-Controlled 
Trial Assessing the 
Efficacy and Safety
of Proton Pump
Inhibitor
Lansoprazole in 
Infants with 
Symptoms of
Gastroesophageal 
Reflux Disease 
(2009, Orenstein, 
et al). 
Double-
blind, 
randomized, 
placebo-
controlled 
trial 
Infants aged 28 
days to < 12 
months and 
preterm infants 
with corrected
age of 44 
weeks PCA but 
< 12 months. 
Treatment with 
lansoprazole for 
gastroesophageal reflux 
disease.
This study detected no difference in 
efficacy between lansoprazole and 
placebo for symptoms attributed to
GERD in infants aged 1 to 12 
months.  Significant adverse events, 
particularly lower respiratory tract 
infections occurred more frequently
with lansoprazole than with 
placebo. 
Level 
II/Grade 
B 
Good study 
design. Power 
was suggested at 
160 subjects, 162 
enrolled. Crying 
was a part of the 
inclusion criteria 
and is 
nonspecific for 
GERD.
Yes
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 Table I 
Article Type of Participants Theme/Treatment Outcomes Level of Study strengths/ Recommend 
Title/Author Article/Study Research Weaknesses for use 
/Grade in review 
Efficacy of 40 of the 50 Infants Conservative therapy Two weeks of conservative therapy Level Non randomized Yes
Conservative infants taught in the primary measures can improve symptoms in II/Grade trial. Small 
Therapy as Taught enrolled in care setting and its 78% of infants with GERD who are B sample size.  
in the Primary Care the impact on symptoms of seen and treated in the primary care Conservative 
Setting for Prospective, gastroesophageal reflux setting, normalizing symptoms in therapy can be 
Symptoms double-blind, disease. 24%.   initiated without 
Suggesting Infant placebo- side effects to 
Gastroesophageal controlled patients. 
Reflux (2008, randomized 
Orenstein & clinical trial 
McGowan). of an oral 
solution of an
H2RA. 
Should Systematic Children aged Domperidone for the There was limited evidence Level Review of Yes
Domperidone Be review of 1 month to 11 treatment of available. There was no robust I/Grade randomized 
Used For the randomized years old. gastroesophageal reflux evidence of efficacy for the A controlled trials. 
Treatment of controlled disease treatment of GOR with 
Gastro­ trials. domperidone in young children. 
oesophageal Reflux 
in Children? 
Systematic Review 
of Randomized 
Controlled Trials in 
Children Aged 1 
Month to 11 Years 
Old (2005, 
Pritchard, et al). 
Letter To The Editorial Babies The use of carob bean No outcomes noted. Level No No 
Editor (2005, comment/ gum thickeners for VI/Grade recommendation 
Puntis, J. W. L.) expert treatment of D for use. 
opinion gastroesophageal 
reflux. 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Stop the PPI 
Express: They 
Don’t Keep Babies 
Quiet! (2009,
Putnam, P. E.) 
Editorial 
comment/ 
expert 
opinion
Babies Treatment with proton 
pump inhibitors and 
their affect on 
gastroesophageal 
reflux. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No. 
Commentary
(2005, Ravazzolo, 
C. J.) 
Editorial 
comment/ 
Expert 
opinion
Infants Treatments for 
gastroesophageal 
reflux. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No. 
Commentary
(2008, Savino & 
Castagno) 
Editorial 
comment/ 
Expert 
opinion
Infants The use of thickened 
formulas for the 
treatment of 
gastroesophageal 
reflux. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No. 
Overprescription of 
Antireflux 
Medications for 
Infants With 
Regurgitation 
(2008, Savino & 
Castagno) 
Editorial 
comment/ 
Expert 
opinion
Infants Use of antireflux 
medications for infants 
with regurgitation.
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No. 
Pediatric 
Gastroesophageal 
Reflux Disease 
Case Study (2009, 
Smith, et al) 
Case study Infant Case study showing 
manifestations of 
GERD in an infant 
beginning at 7 months 
of age. 
Outcome of the combination of 
pharmacotherapy with 
Lansoprazole, nutritional 
supplementation, and behavioral 
therapy were successful in treating 
GERD.
Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
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Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Non­
pharmacologic 
Therapy May Be 
Effective For 
Infants With 
Gastroesophageal 
Reflux (2008,
Sondheimer, J.) 
Editorial 
Comment/ex 
pert opinion
Infants Conservative therapy in 
the treatment of GERD. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
Safety and 
Pharmacodynamics
of Lansoprazole in 
Patients with 
Gastroesophageal 
Reflux Disease 
Aged < 1 Year 
(2008, Springer, et 
al). 
Single and 
repeated 
dose, 
randomized, 
parallel-
group, open-
label, 
multicenter 
study 
Infants less 
than 1 year of 
age. 
Effect of lansoprazole 
on the symptoms of 
GERD.
Over 5 days of daily dose 
administration, lansoprazole was 
well tolerated in neonates and 
infants. Lansoprazole increased the 
percentage of time that intragastric 
pH was above 3, 4, 5, and 6 over the 
24 hour post-dose period on days 1 
and 5 when compared to baseline.   
A decrease in the frequency of 
GERD symptoms was also observed 
although the study was not designed 
to assess clinical benefit in children 
<1 year of age. 
Level 
II/Grade 
B 
Good study 
design. Small 
sample size at 24 
infants. 
Yes
Gastroesophageal 
Reflux in Infancy
and Childhood
(2006, Suwandhi, 
et al). 
Review 
Article 
Infants and 
Children 
Review looking at 
GERD and its 
symptoms, diagnosis 
and treatments.  
Treatment objectives are relief of 
symptoms.  Avoidance of certain 
foods that exacerbate acid reflux, 
lifestyle modifications, nutritional 
changes including thickening of 
feeds. Hypoallergenic formula is 
supported in infants with recurrent 
emesis.  H2 receptor antagonists or 
proton pump inhibitors would be 
the next line of treatment.  
Prokinetic drugs remain 
controversial for treatment.  Next 
step surgical intervention. 
Level 
I/Grade 
B 
Review article
focusing on
infants and 
children. 
Yes
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Effect of an Amino 
Acid-based Milk – 
Neocate – on 
Gastro­
oesophageal Reflux 
in Infants Assessed 
by Combined
Intraluminal 
Impedance/pH
(2006, Thomson, et 
al). 
Non 
randomized 
study with 
patients as 
their own 
control.
Infants under 
12 months of 
age with 
clinically
suggestive 
symptoms of 
GOR.
Treatment with 
Neocate to impact 
symptoms of GOR.
The trial revealed a symptomatic 
improvement on Neocate but cannot 
be attributed to any positive effect 
on GOR. There was no observable 
difference in any reflux parameter 
as measured by two methods. 
Level 
III/Grade 
B 
Non-randomized.  
Very small 
sample size of 11 
infants. 
Yes
Histamine H2 
Receptor 
Antagonists and 
Proton Pump
Inhibitors: Best 
Options for Gastro­
oesophageal Reflux 
in Children (2010, 
Tighe, M., et al). 
Review 
article.
Children Best pharmacotherapy
for the treatment of 
GOR.
Conservative approaches can assist 
in the treatment of GOR. H2 
receptor antagonists decrease acid 
secretion. Ranitidine, cimetidine 
and famotidine have shown efficacy
superior to placebo for symptom
relief and oesophageal healing in 
many clinical trials.  Proton pump 
inhibitors are considered the most 
effective acid suppressant 
medications. There is no data for 
use in infants under the age of 6 
months or on the long-term safety in 
children. Prokinetic agents such as 
Metoclopramide and Domperidone, 
limited benefit.  There is 
insufficient evidence to recommend 
erythromycin and Bethanechol in 
children with GOR.  Antacids work 
in the short term.  Gaviscon Infant, 
can improve symptoms of GOR.  
Sulcrafate may improve symptoms.
Level 
I/Grade 
B 
Review focusing 
on infants.
Yes
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Current 
Pharmacological 
Management of 
Gastro-Esophageal 
Reflux in Children 
– An Evidence-
Based Systematic 
Review (2009, 
Tighe, et al). 
Systematic 
Review 
Children Pharmacologic 
management of 
gastroesophageal 
reflux. 
Gaviscon Infant acts as a feed 
thickener and prevents reflux by
increasing the viscosity of feeds.  
Should be used with caution in 
children at risk for dehydration.  
Some evidence that it is effective.
There is insufficient evidence to 
make a recommendation regarding 
the role of antacids in children with 
GERD. Oral Ranitidine provides 
symptomatic relief and endoscopic 
improvement of esophagitis in 
children with GER.  If the initial 
dose of ranitidine fails to relieve 
symptoms, a higher dose of 
ranitidine or a proton-pump 
inhibitor should be tried. There is 
evidence to support the efficacy of 
cimetidine in children with GERD 
but there are significant adverse 
effects. Omeprazole is effective in 
improvement of symptoms, pH 
probe findings and endoscopic 
findings with a good tolerability and 
safety profile.  Omeprazole should 
be the first-line treatment in severe 
esophagitis in children. It is dose-
dependent. Less data available for 
lansoprazole but it appears to be 
effective in children. Lansoprazole 
is dose dependent. Pantoprazole 
appears to be effective with limited 
data. Esomeprazole also has limited 
data but appears to be effective.  
There is limited efficacy of 
metoclopramide in children with 
Level 
I/Grade 
A 
Systematic 
review.
Yes
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GER and significant adverse 
effects. There is little evidence of 
benefit from Domperidone but there 
are also no serious side effects 
noted. There is currently not 
enough evidence to draw 
conclusions on the use of 
erythromycin.  No evidence exists 
to suggest efficacy of bethanechol 
in reducing GER in children.  
Further evidence is needed to assess 
the clinical benefit of sucralfate in 
GERD. 
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Controversies in 
the Treatment of 
Gastroesophageal 
Reflux Disease in 
Preterm Infants 
(2009, Tipnis & 
Tipnis).
Review 
Article 
Preterm Infants Review of varies 
treatments used in the 
treatment of GERD 
Positioning: sitting exacerbates 
GER. Faster gastric emptying can 
be seen with less liquid reflux and 
feeding on right side followed by 
change to left side after 1 hour. 
Thickening of feeds reduces number 
and height of non acid reflux
episodes but does not decrease acid 
reflux events. Continuous drip 
feeding reduces vomiting and reflux 
symptoms but chronic use of 
indwelling tubes that cross the 
gastroesophageal junction is 
associated with increased 
regurgitation and esophagitis.  Oral 
antacids and surface agents such as 
alginates have been poorly studied 
in preterm infants.  Chronic antacid 
use in preterm infants is not 
recommended.  Prokinetic agents 
have limited role in the treatment of 
GERD because there is a lack of 
efficacy shown in the preterm
population.  The efficacy of 
bethanechol has not been 
determined.  Erythromycin has had 
mixed results in improving reflux 
scores and feeding tolerance in 
preterm infants.  Baclofen reduced 
the frequency of transient lower 
esophageal sphincter relaxation, 
decreased acid reflux, and 
accelerated gastric emptying in a 
placebo-controlled study in infants.  
There have been neurologic side 
Level 
I/Grade 
B 
Review article, 
few studies 
involving preterm
infants. 
Yes
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effects in adults. Ranitidine has 
been shown to protect against 
steroid-induced ulcers in patients 
who have chronic lung disease, in 
the preterm population.  Famotidine 
reduced the frequency of 
regurgitation and at a larger dose 
reduced crying time in preterm
infants; the pharmacokinetics and 
efficacy have not been studied in 
preterm infants.  The 
pharmacokinetic and 
pharmacodynamic properties of 
lansoprazole and omeprazole have 
been studied in a very small number 
of neonates. Omeprazole 
normalized the reflux index in a 
small number of infants and 
reduced the percentage of time
where the intragastric pH was less
than 4 but found no difference in 
the frequency of reflux symptoms in 
the placebo and omeprazole arms at 
the end of treatment.  An increased 
risk of necrotizing enterocolitis as 
found with chronic acid 
suppression. In another study, acid 
suppression with either H2RAs or 
proton pump inhibitors was 
associated with an increased 
incidence of acute gastroenteritis 
and community-acquired 
pneumonia.  There are various 
surgical interventions that will not 
be addressed in this review.  
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Multicenter, 
Randomized, 
Double-Blind
Study Comparing 
10, 20, and 40 mg
Pantoprazole in 
Children (5-11 
Years) with 
Symptomatic
Gastroesophageal 
Reflux Disease 
(2006, Tolia, et al). 
Randomized, 
double-blind,
parallel 
group study.
Children aged 
5 to 11 years 
with confirmed 
symptomatic 
GERD.
Treatment with 
Pantoprazole for 
symptom relief in 
GERD.
Pantoprazole (20 and 40 mg) is 
effective in reducing endoscopically
proven GERD symptoms in 
children. Both dosages 
significantly reduced symptoms as 
early as 1 week. 
Level 
II/Grade 
B 
Good study 
design. Small 
sample size of 53 
patients. Did not 
specifically
address infants or 
neonates. 
Yes/Limited 
Effect of Body 
Position Changes 
on Postprandial 
Gastroesophageal 
Reflux and Gastric 
Emptying in the 
Healthy Premature 
Neonate (2007, 
Van Wijk, et al). 
Randomized, 
cross over 
trial. 
Healthy
preterm infants, 
without 
symptoms 
related to 
GERD.
Effect of position on
symptoms related to 
GERD, left side to right
side and conversely,
right side to left side. 
Right lateral positioning for the first 
postprandial hour with a position 
change to the left thereafter
promotes gastric emptying and 
reduces liquid gastroesophageal 
reflux in the late postprandial 
period.
Level 
II/Grade 
B 
Very small 
sample size but 
does show 
promise with 
conservative 
interventions. 
Yes
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Gastroesophageal 
Reflux: Medical 
Treatment (2005, 
Vandenplas, Y.) 
Review 
Article 
Children Treatments for 
gastroesophageal 
reflux. 
Conservative therapies and 
reassurance are the best first 
approach. Prone position has 
lowest incidence of GER; left 
lateral position has intermediate 
incidence of GER. The prone 
position with head elevated 30 
degrees has the lowest incidence of 
GER. Cornstarch as a thickening 
agent shows decreased esophageal 
acid exposure time. Prokinetic 
agents such as metoclopramide, 
domperidone and cisapride have 
limited efficacy.  There is limited 
data for efficacy of erythromycin.  
There is no pediatric data for 
prucalopride, clebopride, or
itopride. Baclofen has some limited 
data to support its use.  Experience 
with antacids is limited in infants.  
Ranitidine and Nizatidine are not 
well studied in children. 
Omeprazole and lansoprazole have 
been best studied in children and are 
efficacious. Long term use of 
gastric acid inhibitors has been 
linked to bacterial overgrowth.  
Level 
I/Grade 
B 
Review article
focusing on
children. Not too 
specific for 
infants and 
neonates. 
Yes
Thickened Infant 
Formula Does 
What It Has To 
Do: Decrease
Regurgitation 
(2009, Vandenplas, 
Y). 
Editorial 
comment/ 
Expert 
opinion
Infants Use of thickening 
agents in the treatment 
of gastroesophageal 
reflux disease. 
No outcomes noted. Level 
VI/Grade 
D 
No 
recommendation 
for use. 
No 
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
A Preliminary 
Report On the 
Efficacy of the 
Multicare AR-Bed 
in 3-week-3­
month-old Infants 
On Regurgitation, 
Associated 
Symptoms and
Acid Reflux (2010, 
Vandenplas, et al). 
Prospective 
evaluation in 
an open 
intervention 
pilot study. 
3-week to 3­
month old 
infants. 
Use of multicare AR 
(anti-reflux) bed and its 
effect on 
gastroesophageal 
reflux. 
The 40 degree position of the 
incline bed decreased regurgitation 
in a statistically and clinically 
significant way.
Level 
III/Grade 
B 
Very small 
sample size (30).  
Non-randomized, 
non controlled 
trial. High “drop 
out” rate due to 
infants 
discomfort in the 
inclined position. 
Yes/Limited 
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
The Diagnosis and 
Management of 
Gastro­
oesophageal Reflux 
in Infants (2005, 
Vandenplas, et al). 
Review 
article.
Infants. Treatment options for 
gastroesophageal 
reflux. 
Prone position has lowest incidence 
of GER; left lateral position has 
intermediate incidence of GER.  
The prone position with head 
elevated 30 degrees has the lowest 
incidence of GER. The risk of 
SIDS must be considered with 
positioning.  Reduction in food 
volumes can decrease the number of 
regurgitations.  Lifestyle changes 
can impact reflux.  Cow’s milk 
allergy may impact GORD,
consider non cow’s milk formula.  
Cornstarch as a thickening agent 
shows decreased esophageal acid 
exposure time. Because of 
nutritional concerns, commercially
thickened formula is preferred to 
thickening agents added to formula.  
Prokinetic agents such as 
metoclopramide, domperidone and 
cisapride have limited efficacy.  
There is limited data for efficacy of 
erythromycin.  There is no or very
little pediatric data for ondansetron, 
tegaserod, prucalopride, clebopride, 
or itopride.  Experience with 
antacids is limited in infants. 
Alginate-based, raft forming 
formulations which, in the presence 
of gastric acid, precipitates forming 
a gel, and later a foam-like pH 
neutral barrier in the stomach. 
Aluminum containing antacids 
should not be given to infants and 
Level 
I/Grade 
B 
Review article
with many older 
articles.
Yes
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 Table I 
toddlers because of the nutritional 
and neurotoxic side effects.  
Sucralfate, which also contains 
aluminum, should not be used in 
infants. Ranitidine, famotidine, and 
Nizatidine are not well studied in 
children. Omeprazole and 
lansoprazole have been best studied 
in children and are efficacious.  
Long term use of gastric acid 
inhibitors has been linked to
bacterial overgrowth.
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 Table I Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Gastroesophageal 
Reflux in Infancy,
A Common But 
Challenging 
Presentation (2008, 
Weill, V). 
Review 
Article 
Infants Treatment options for 
gastroesophageal reflux 
disease.
Uncomplicated GER in infants 
requires time as it often resolves by
the first birthday.  Conservative 
therapy consisting of lifestyle and 
behavioral management would be 
the next line of defense.  Small, 
more frequent feedings with 
frequent burping can help reduce 
symptoms of GER.  Cow’s milk 
protein allergy may be the cause of 
GER symptoms, trial of 
hypoallergenic formula for 
determination is recommended.  
Prone positioning decreases reflux 
but the risk of SIDS is of greater 
concern. Supine positioning is still 
recommended.  A smoke-free 
environment may be beneficial for 
babies with reflux. Thickening 
agents does not reduce the acid 
reflux but regurgitation episodes.  
The acid is still there, but it cannot 
be seen in vomiting. Thickening of 
feeds can be used to treat reflux.  
Antacids are not recommended for 
long-term use.  Ranitidine, 
famotidine, and Nizatidine are not 
well studied in children. 
Omeprazole and lansoprazole have 
been best studied in children and are 
efficacious.  They are not approved 
for use in infants.  
Level 
I/Grade 
B 
Yes 
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 Table I 
Article 
Title/Author
Type of 
Article/Study 
Participants Theme/Treatment Outcomes Level of 
Research 
/Grade 
Study strengths/ 
Weaknesses
Recommend 
for use 
in review 
Cornstarch 
Thickened Formula 
Reduces 
Oesophageal Acid 
Exposure Time in 
Infants (2005, 
Xinias, et al).
Blinded, 
randomized 
controlled 
trial. 
Formula-fed 
infants with a 
mean age of 93 
days.
Cornstarch thickened 
formula and its effect 
on gastroesophageal 
reflux. 
A formula thickened with a 
specifically treated cornstarch 
reduces oesophageal acid exposure 
and reduces the frequency of 
clinical symptoms.  In addition, the 
group receiving the cornstarch 
thickened formula had better weight 
gain – possibly related to decreased 
vomiting in part.   
Level 
II/Grade 
B 
Randomized 
controlled trial 
with relatively 
large sample size.
Yes
Age-Dependent Single and 20 neonates Treatment with The pharmacokinetics of Level Good study Yes
Pharmacokinetics repeated (<28 days old) lansoprazole and the lansoprazole are age dependent.  II/Grade design, small 
of Lansoprazole in dose, and 20 infants age dependent dose Pediatric patients aged < 10 weeks B sample size.
Neonates and randomized, (>28 days  but needed to treat require a lower dose of lansoprazole 
Infants (2008, 
Zhang, et al). 
open-label, 
multicenter 
study.
<1 year old) gastroesophageal 
reflux. 
than pediatric patients aged > 10 
weeks to achieve similar plasma 
exposure. Effectiveness of
lansoprazole in subjects < 1 year old 
has not been established and was 
not addressed in this study. 
Pharmacokinetic 
Properties of 
Esomeprazole in 
Children Aged 1 to 
11 Years with
Symptoms of
Gastroesophageal 
Reflux Disease: A 
Randomized, 
Open-Label Study
(2006, Zhao, et al) 
Randomized, 
open label 
study.
Uncontrolled.
Children 1 – 11 
years old 
stratified into 
groups: 1-5 
years and 6-11 
years. 
Effects of 
Esomeprazole of 
children in the 
treatment of 
gastroesophageal reflux 
disease.
This study shows that the 
pharmacokinetic properties of 
esomeprazole in children aged 1 to
11 years who have GERD may be 
both dose and age dependent.  The 
metabolism of esomeprazole per 
kilogram of body weight is more 
rapid in younger (aged 1-5 years) 
children than in older (aged 6-11 
years) children.  Doses were well 
tolerated. This study did not 
address the effectiveness of
esomeprazole. 
Level 
II/Grade 
B 
Randomized trial 
without control.  
Small sample 
size of 31 
children. 
Yes
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Chapter 4: Conclusions 
Gastroesophageal reflux disease (GERD) is often assumed in the neonatal and infant 
population due to feeding intolerance and behavioral manifestations.  To this day, there is no 
generally-agreed-upon test to determine if an infant is suffering from GERD.  Unfortunately, 
even without diagnosis, GERD is treated frequently, especially in the hospital setting.  There are 
not often practice guidelines for the treatment of GERD in the infant population.  At the very 
least, it would be important to start with conservative treatments before moving towards diet 
changes and medications, as the evidence supports.   
The majority of the articles and studies included in this systematic review focused on 
neonates and infants, except those studies looking at medications.  There were relatively few 
well designed studies focusing on currently prescribed medications in the neonatal and infant 
populations. This can cause inappropriate dosing and perhaps prescribing of medications that are 
not well tolerated in infants if not well studied.
There were many studies that identified some interventions not to be efficacious.  This is 
valuable information as it eliminates useless treatments from an approach to care.  In addition, 
some medications that have been studied are not effective or may actually be harmful, such as 
cisapride.
Best Practice for the Treatment of Gastroesophageal Reflux
There are evidence-based best practices for the treatment of gastroesophageal reflux 
disease. Initially, conservative therapies should be attempted as their side effects are minimal.  
Parental reassurance and education had significant results related to reducing the symptoms of 
gastroesophageal reflux. Symptoms of reflux diminish and even disappear over time, supporting 
this intervention (Orenstein & McGowan, 2008). If further treatment is warranted, there is 
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evidence that prone or left lateral positioning increases gastric emptying time and, therefore, 
decreases gastroesophageal reflux events.  This positioning must be used with caution because of
the risk of Sudden Infant Death Syndrome (SIDS).  Cardiac monitoring must be used in 
conjunction with prone or left side positioning; therefore, in most cases, this intervention cannot 
be recommended for use in the hospital setting.  One randomized crossover trial by Van Wijk, et 
al, (2007), showed that a right lateral position for the first hour following a feeding with a change 
to the left thereafter promoted gastric emptying.  This had a very small sample size, but, with 
cardiac monitoring, could be used to decrease symptoms. 
Feeding interventions can also be useful in the treatment of gastroesophageal reflux 
disease (GERD) and are still considered to be conservative.  Smaller, more frequent feedings can 
decrease the symptoms of GERD.  In addition, thickening of feedings can also decrease reflux 
episodes. 
If these conservative therapies are not successful in treating GERD, there are some
medications that have proven to be successful in either their acid suppression effects or their 
ability to increase gastric emptying times.  It is important, especially with the use of 
pharmaceuticals, to monitor the effects of the medications and determine the continuing need for 
intervention.
Recommendations for Future Research 
More research in the diagnosis of gastroesophageal reflux should be done so that 
treatment without diagnosis can be avoided.  There is not a generally agreed upon “gold 
standard” to determine the presence of GERD.  The diagnosis of GERD is made based upon 
symptoms such as vomiting, arching, crying, and irritability.  These are vague symptoms that 
may be explained by another diagnosis.  In addition, having an infant with GERD or suspected 
           
 
 
 
 
 
 
 
 
 
 
 
 
54 
GERD is stressful for families and may be expensive.  It will be important in the future with 
stricter controls on healthcare dollars to determine true cases of GERD and treat them
appropriately and to avoid treatment when GERD is not present. 
Recommended approach to the treatment of GERD 
The following is a listing of treatments from conservative to pharmacotherapy that can be 
used in the treatment of GERD in a stepped approach: 
	 Parental reassurance should be used as a first treatment as it is the easiest, least invasive 

treatment for infant regurgitation as symptoms usually decrease and disappear over time
 
(Grade B).
 
	 Prone or left-lateral positioning after feedings can reduce GERD in preterm infants but 

cannot be used without cardiac monitoring because of the risk of SIDS; if this is to be 

used as an early intervention, the patient must be continuously monitored and this must 

be discontinued prior to discharge home (Grade B). 

	 Faster gastric emptying can be seen with less liquid reflux and feeding on right side 

followed by change to left side after 1 hour.  This approach must also include cardiac 

monitoring because of the risk of SIDS (Grade B). 

	 Small, slow, and more frequent feedings (with frequent burping) in a relaxed 
environment are helpful to infants with delayed gastric emptying (Grade B). 

 Eliminating exposure to cow’s milk (Grade B). 

 Thickened feedings utilizing a commercially available product such as Enfamil AR 

because of the balanced nutrition in commercial products (Grade B). 

 Cereal thickened formula (rice or oatmeal) can be used to reduce the frequency of 

regurgitation (Grade B). 
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	 Cornstarch can be used to thicken formula if commercially available products or cereal 
for thickening are unsuccessful (Grade B). 
 Hypoallergenic formula is supported in infants with recurrent emesis (Grade B). 
 Gaviscon Infant can be used as it increases the viscosity of feeds and reduces reflux 
(Grade B).
 Ranitidine can be used as a first line medication treatment (Grade B).
 Omeprazole can be limitedly recommended in children under 2 years, but it is better 
studied in older children (Grade B). 
 Lansoprazole is well tolerated in neonates and infants but its efficacy is only established 
in children older than 1 year (Grade B). 
	 Esomeprazole does have acid suppressive effects in infants older than 1 month at a dose 
of 1mg/kg; systemic exposure in preterm infants and neonates at a dose of 0.5mg/kg 
showed acid suppression but no effect on actual reflux events.  Esomeprazole is only 
approved for use in children older than 1 year (Grade B). 
	 Cimetidine can be recommended limitedly for reduced regurgitation; it is not 

recommended for preterm infants (Grade B). 

Limitations to the Study 
The main limitations to this study were the ability to correlate the available studies on 
drug therapies done on adults to the neonatal and infant populations.  Very few studies on 
pharmacologic agents and their efficacy in the neonatal/infant population have been 
completed although their use is widespread (Orenstein & Hassall, 2007).  Not all review 
articles or studies were limited to the target population or the inclusion criteria of children up 
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to five years of age. It was difficult in some instances to extrapolate data for the target 
population. 
Articles reviewed for this study demonstrated varied designs and methodologies.  In 
many of the studies and articles reviewed, there were small sample sizes.  Despite limitations 
to some of the studies and review articles, there are core themes that can be applied to the 
target population of neonates and infants. 
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